Literature DB >> 18843263

Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite.

H X Zheng1, Y Huang, L A Frassetto, L Z Benet.   

Abstract

The effects of single doses of intravenous (IV) ciprofloxacin and rifampin and of multiple doses of rifampin on glyburide exposure and blood glucose levels were investigated in nine healthy volunteers. A single IV dose of rifampin significantly increased the area under the concentration-time curve (AUC) of glyburide and its metabolite. Blood glucose levels were significantly lower than those observed after dosing with glyburide alone. Multiple doses of rifampin induced an increase in liver enzyme levels, leading to a marked decrease in glyburide exposure and blood glucose levels. When IV rifampin was administered after multiple doses of rifampin, the inhibition of hepatic uptake transporters masked the induction effect; however, the relative changes in AUC for glyburide and its hydroxyl metabolite were similar to those seen under noninduced conditions. The studies reported here demonstrate how measurements of the levels of both the parent drug and its primary metabolite are useful in unmasking simultaneous drug-drug induction and inhibition effects and in characterizing enzymatic vs. transporter mechanisms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18843263      PMCID: PMC3582657          DOI: 10.1038/clpt.2008.186

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  33 in total

1.  Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects.

Authors:  P L M van Giersbergen; A Treiber; R Schneiter; H Dietrich; J Dingemanse
Journal:  Clin Pharmacol Ther       Date:  2007-01-24       Impact factor: 6.875

2.  Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.

Authors:  Mikko Niemi; Ingolf Cascorbi; Ramona Timm; Heyo K Kroemer; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacol Ther       Date:  2002-09       Impact factor: 6.875

3.  Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes.

Authors:  Justine L Lam; Leslie Z Benet
Journal:  Drug Metab Dispos       Date:  2004-11       Impact factor: 3.922

4.  Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A.

Authors:  Yoshihisa Shitara; Tomoo Itoh; Hitoshi Sato; Albert P Li; Yuichi Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  2003-02       Impact factor: 4.030

Review 5.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918.

Authors:  Chi-Yuan Wu; Leslie Z Benet
Journal:  Drug Metab Dispos       Date:  2003-11       Impact factor: 3.922

7.  Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay.

Authors:  Yvonne Y Lau; Chi-Yuan Wu; Hideaki Okochi; Leslie Z Benet
Journal:  J Pharmacol Exp Ther       Date:  2003-11-21       Impact factor: 4.030

8.  Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation.

Authors:  Rommel G Tirona; Brenda F Leake; Allan W Wolkoff; Richard B Kim
Journal:  J Pharmacol Exp Ther       Date:  2003-01       Impact factor: 4.030

9.  Refractory hypoglycemia from ciprofloxacin and glyburide interaction.

Authors:  George Lin; Daniel P Hays; Linda Spillane
Journal:  J Toxicol Clin Toxicol       Date:  2004

10.  Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide.

Authors:  Tanja Busk Bidstrup; Nicolaj Stilling; Per Damkier; Birgitte Scharling; Mikael Søndergård Thomsen; Kim Brøsen
Journal:  Eur J Clin Pharmacol       Date:  2004-03-19       Impact factor: 2.953

View more
  40 in total

1.  Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study.

Authors:  Brooke Harrison; Mindy H Magee; Arun Mandagere; Gennyne Walker; Christopher Dufton; Linda S Henderson; Ramesh Boinpally
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).

Authors:  Manthena V Varma; Stefanus J Steyn; Charlotte Allerton; Ayman F El-Kattan
Journal:  Pharm Res       Date:  2015-07-09       Impact factor: 4.200

3.  Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19.

Authors:  Alice Ban Ke; Srikanth C Nallani; Ping Zhao; Amin Rostami-Hodjegan; Jashvant D Unadkat
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

Review 4.  The role of transporters in the pharmacokinetics of orally administered drugs.

Authors:  Sarah Shugarts; Leslie Z Benet
Journal:  Pharm Res       Date:  2009-06-30       Impact factor: 4.200

Review 5.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

6.  BDDCS applied to over 900 drugs.

Authors:  Leslie Z Benet; Fabio Broccatelli; Tudor I Oprea
Journal:  AAPS J       Date:  2011-08-05       Impact factor: 4.009

Review 7.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

Review 8.  Drug-drug interaction studies: regulatory guidance and an industry perspective.

Authors:  Thomayant Prueksaritanont; Xiaoyan Chu; Christopher Gibson; Donghui Cui; Ka Lai Yee; Jeanine Ballard; Tamara Cabalu; Jerome Hochman
Journal:  AAPS J       Date:  2013-03-30       Impact factor: 4.009

Review 9.  Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage?

Authors:  Sarah Talavera Pons; Geraldine Lamblin; Anne Boyer; Valérie Sautou; Armand Abergel
Journal:  Eur J Clin Pharmacol       Date:  2014-05-10       Impact factor: 2.953

10.  Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins.

Authors:  H Schelleman; X Han; C M Brensinger; S K Quinney; W B Bilker; D A Flockhart; L Li; Sean Hennessy
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.